An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis

References

• Thompson EJ. Cerebrospinal fluid proteins: a biochemical approach. Amsterdam: Elsevier Sciences Ltd; 1988.
   Google Scholar
• Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111–147ra111.
   PubMed Web of Science ®Google Scholar
• Aspelund A, Antila S, Proulx S, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212:991–999.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–341.
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Altenhofen B, Riegel A, et al. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol. 1997;41:326–333.
   PubMed Web of Science ®Google Scholar
• Malekzadeh A, de Groot V, Beckerman H, et al. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods. 2012;56:508–513.
   PubMed Web of Science ®Google Scholar
• Felgenhauer K. Barrier concepts and CSF analysis. J Neurol. 1992;239:59–60.
   PubMed Web of Science ®Google Scholar
• Bar-Or A. Multiple sclerosis and related disorders: evolving pathophysiologic insights. Lancet Neurol. 2016;15:9–11.
   PubMed Web of Science ®Google Scholar
• Koch M, Kingwell E, Rieckmann P, et al. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039–1043.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–721.
   PubMed Web of Science ®Google Scholar
• Harding KE, Wardle M, Moore P, et al. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:13–19.
   PubMed Web of Science ®Google Scholar
• Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
   PubMed Web of Science ®Google Scholar
• Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011;76:S14–25.
   PubMed Web of Science ®Google Scholar
• Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85:1183–1189.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, de Stefano N, Pia Sormani M, et al. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4:460–469.
   PubMed Web of Science ®Google Scholar
• Filippini G, del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:Cd008933.
   Google Scholar
• Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–568.
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846.
   PubMed Web of Science ®Google Scholar
• Andersson M, Alvarez-Cermeño J, Bernardi G. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62:865–870.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Christiansen M, Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler. 1998;4:127–131.
   PubMed Web of Science ®Google Scholar
• Reiber H. Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99–107.
   PubMed Web of Science ®Google Scholar
• Auer M, Hegen H, Zeileis A, et al. Quantitation of intrathecal immunoglobulin synthesis - a new empirical formula. Eur J Neurol. 2016;23:713–721.
   PubMed Web of Science ®Google Scholar
• Marchioni E, Ravaglia S, Montomoli C, et al. Postinfectious neurologic syndromes: a prospective cohort study. Neurology. 2013;80:882–889.
   PubMed Web of Science ®Google Scholar
• Lourenco P, Shirani A, Saeedi J, et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler. 2013;19:577–584.
   PubMed Web of Science ®Google Scholar
• Tur C, Montalban X. CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: no. Mult Scler. 2013;19:717–718.
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Olsson T. Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: yes. Mult Scler. 2013;19:714–716.
   PubMed Web of Science ®Google Scholar
• Hutchinson M. CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: commentary. Mult Scler. 2013;19:719–720.
   PubMed Web of Science ®Google Scholar
• Dobson R, Ramagopalan S, Davis A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909–914.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21:1013–1024.
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70:1079–1083.
   PubMed Web of Science ®Google Scholar
• Dalla Costa G, Passerini G, Messina MJ, et al. Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. J Neuroimmunol. 2015;289:62–67.
   PubMed Web of Science ®Google Scholar
• Rojas JI, Tizio S, Patrucco L, et al. Oligoclonal bands in multiple sclerosis patients: worse prognosis? Neurol Res. 2012;34:889–892.
   PubMed Web of Science ®Google Scholar
• Ferreira D, Voevodskaya O, Imrell K, et al. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. J Neuroimmunol. 2014;274:149–154.
   PubMed Web of Science ®Google Scholar
• Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse myelitis. Eur J Neurol. 2012;69:357–362.
   Google Scholar
• Skov AG, Skov T, Frederiksen JL. Oligoclonal bands predict multiple sclerosis after optic neuritis: a literature survey. Mult Scler. 2011;17:404–410.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Klein EP, Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology. 2012;78:1986–1991.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller AE. Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology. 2012;78:1904–1906.
   PubMed Web of Science ®Google Scholar
• Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol. 2013;262:1–10.
   PubMed Web of Science ®Google Scholar
• Schaffler N, Kopke S, Winkler L, et al. Accuracy of diagnostic tests in multiple sclerosis–a systematic review. Acta Neurol Scand. 2011;124:151–164.
   PubMed Web of Science ®Google Scholar
• Heussinger N, Kontopantelis E, Gburek-Augustat J, et al. Oligoclonal bands predict multiple sclerosis in children with optic neuritis. Ann Neurol. 2015;77:1076–1082.
   PubMed Web of Science ®Google Scholar
• Chabas D, Ness J, Belman A, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 2010;74:399–405.
   PubMed Web of Science ®Google Scholar
• Lee CG, Lee B, Lee J, et al. The natural course of clinically isolated syndrome in pediatric patients. Brain Dev. 2015;37:432–438.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–1104.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–2912.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol. 2008;7:852–858.
   PubMed Web of Science ®Google Scholar
• Jones GW, Jones SA. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology. 2016;147:141–151.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008;14:688–693.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med. 2014;6:248ra106.
   PubMed Web of Science ®Google Scholar
• Bankoti J, Apeltsin L, Hauser S. In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol. 2014;75:266–276.
   PubMed Web of Science ®Google Scholar
• Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol. 2005;4:195–202.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. EBV and autoimmunity. Curr Top Microbiol Immunol. 2015;390:365–385.
   PubMed Web of Science ®Google Scholar
• Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132:3318–3328.
   PubMed Web of Science ®Google Scholar
• Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115:1352–1360.
   PubMed Web of Science ®Google Scholar
• Virtanen JO, Wohler J, Fenton K, et al. Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult Scler. 2014;20:27–34.
   PubMed Web of Science ®Google Scholar
• Brandle SM, Obermeier B, Senel M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016;113:7864–7869.
   PubMed Web of Science ®Google Scholar
• Sindic CJ, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol. 1994;54:75–80.
   PubMed Web of Science ®Google Scholar
• Stich O, Kluge J, Speck J, et al. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients. Acta Neurol Scand. 2015;131:381–388.
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Vandvik B, Nadj C, et al. The intrathecal immune response in the early stage of multiple sclerosis. J Neurol Sci. 1987;81:45–53.
   PubMed Web of Science ®Google Scholar
• de Bock L, Somers K, Fraussen J, et al. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. J Immunol. 2014;193:2147–2156.
   PubMed Web of Science ®Google Scholar
• Fainardi E, Castellazzi M, Tamborino C, et al. Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. J Neurovirol. 2009;15:425–433.
   PubMed Web of Science ®Google Scholar
• Stich O, Rauer S. Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5-associated paraneoplastic neurological syndromes. Eur J Neurol. 2007;14:650–653.
   PubMed Web of Science ®Google Scholar
• Storstein A, Monstad SE, Honnorat J, et al. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. J Neuroimmunol. 2004;155:150–154.
   PubMed Web of Science ®Google Scholar
• Rauer S, Kaiser R. Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol. 2000;111:241–244.
   PubMed Web of Science ®Google Scholar
• Jarius S, Stich O, Rasiah C, et al. Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci. 2008;268:65–68.
   PubMed Web of Science ®Google Scholar
• Jarius S, Stich O, Speck J, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol. 2010;229:219–224.
   PubMed Web of Science ®Google Scholar
• Vandvik B, Norrby E. Oligoclonal IgG antibody response in the central nervous system to different measles virus antigens in subacute sclerosing panencephalitis. Proc Natl Acad Sci USA. 1973;70:1060–1063.
   PubMed Web of Science ®Google Scholar
• Dörries R, Ter Meulen V. Detection and identification of virus-specific, oligoclonal IgG in unconcentrated cerebrospinal fluid by immunoblot technique. J Neuroimmunol. 1984;7:77–89.
   PubMed Web of Science ®Google Scholar
• Vartdal F, Vandvik B, Michaelsen TE, et al. Neurosyphilis: intrathecal synthesis of oligoclonal antibodies to Treponema pallidum. Ann Neurol. 1982;11:35–40.
   PubMed Web of Science ®Google Scholar
• Porter KG, Sinnamon DG, Gillies RR. Cryptococcus neoformans-specific oligoclonal immunoglobulins in cerebrospinal fluid in cryptococcal meningitis. Lancet. 1977;1:1262.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Hansen K, Sidén A, et al. Intrathecal synthesis of anti-Borrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scand J Immunol. 1993;37:369–376.
   PubMed Web of Science ®Google Scholar
• Kaiser R, Dörries R, Lüer W, et al. Analysis of oligoclonal antibody bands against individual HIV structural proteins in the CSF of patients infected with HIV. J Neurol. 1989;236:157–160.
   PubMed Web of Science ®Google Scholar
• Link H, Cruz M, Gessain A, et al. Chronic progressive myelopathy associated with HTLV-I: oligoclonal IgG and anti-HTLV-I IgG antibodies in cerebrospinal fluid and serum. Neurology. 1989;39:1566–1572.
   PubMed Web of Science ®Google Scholar
• Burgoon MP, Hammack BN, Owens GP, et al. Oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV. Ann Neurol. 2003;54:459–463.
   PubMed Web of Science ®Google Scholar
• Lejon V, Sindic CJ, van Antwerpen MP, et al. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response. Eur J Neurol. 2003;10:711–719.
   PubMed Web of Science ®Google Scholar
• Reiber H. Flow rate of cerebrospinal fluid (CSF): a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122:189–203.
   PubMed Web of Science ®Google Scholar
• Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77:454–467.
   PubMed Web of Science ®Google Scholar
• Goris A, Pauwels I, Gustavsen MW, et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 2015;138:632–643.
   PubMed Web of Science ®Google Scholar
• Leone MA, Barizzone N, Esposito F, et al. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLoS One. 2013;8:e64408.
   Google Scholar
• Harbo HF, Isobe N, Berg-Hansen P, et al. Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. Mult Scler. 2014;20:660–668.
   PubMed Web of Science ®Google Scholar
• Simpson S Jr., Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:1132–1141.
   PubMed Web of Science ®Google Scholar
• Persson L, Longhi S, Enarsson J, et al. Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. J Clin Virol. 2014;61:107–112.
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Bartos A, Egg R, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006;13:913–922.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Ma CS, Brink R, et al. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol. 2013;13:412–426.
   PubMed Web of Science ®Google Scholar
• Altiokka-Uzun G, Tuzun E, Ekizoglu E, et al. Oligoclonal bands and increased cytokine levels in idiopathic intracranial hypertension. Cephalalgia. 2015;35:1153–1161.
   PubMed Web of Science ®Google Scholar
• Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta. 1987;163:319–328.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Avolio C, Lolli F. Between-laboratory variability in oligoclonal IgG band numbering. Clin Chem. 2005;51:270–272.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Lolli F. Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. Clin Chem. 2007;53:1557–1558.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Bergamaschi R, Amato MP, et al. Clinical correlations of CSF single IgG bands. J Neurol. 2005;252:1274–1275.
   PubMed Web of Science ®Google Scholar
• Ceroni M, Camana C, Franciotta DM, et al. Specific activation of B-cell clones within the central nervous system in course of herpes simplex encephalitis. Boll Soc Ital Biol Sper. 1990;66:1223–1230.
   PubMedGoogle Scholar
• Franciotta D, Columba-Cabezas S, Andreoni L, et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol. 2008;200:125–128.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Di Stefano AL, Jarius S, et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol. 2011;230:160–163.
   PubMed Web of Science ®Google Scholar
• Thompson EJ, Freedman MS. Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Adv Neurol. 2006;98:147–160.
   PubMedGoogle Scholar
• Ambrose HE, Granerod J, Clewley JP, et al. Diagnostic strategy used to establish etiologies of encephalitis in a prospective cohort of patients in England. J Clin Microbiol. 2011;49:3576–3583.
   PubMed Web of Science ®Google Scholar
• Kostulas VK. Oligoclonal IgG bands in cerebrospinal fluid. Methodological and clinical aspects. Acta Neurol Scand Suppl. 1985;103:1–112.
   PubMedGoogle Scholar
• Davies G, Keir G, Thompson EJ, et al. The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology. 2003;60:1163–1166.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Brown NN, Barr AE, et al. Monoclonal immunoglobulin bands in the cerebrospinal fluid. Aust N Z J Med. 1991;21:227–229.
   PubMedGoogle Scholar
• Franciotta D, Zardini E, Lolli F. The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology. 2004;62:675; author reply.
   Google Scholar
• Harrison HH. Patient-specific microheterogeneity patterns of monoclonal immunoglobulin light chains as revealed by high resolution, two-dimensional electrophoresis. Clin Biochem. 1992;25:235–243.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Cerebrospinal fluid analysis. Handb Clin Neurol. 2014;122:681–702.
   PubMedGoogle Scholar
• Felgenhauer K, Schadlich HJ, Nekic M, et al. Cerebrospinal fluid virus antibodies. A diagnostic indicator for multiple sclerosis? J Neurol Sci. 1985;71:291–299.
   PubMed Web of Science ®Google Scholar
• Jarius S, Eichhorn P, Jacobi C, et al. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280:98–100.
   PubMed Web of Science ®Google Scholar
• Hottenrott T, Dersch R, Berger B, et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015 Dec;13(12):27.
   Google Scholar
• Luxton RW, Zeman A, Holzel H, et al. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci. 1995;132:11–19.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One. 2009;4:e7638.
   PubMed Web of Science ®Google Scholar
• Hiepe F, Dorner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7:170–178.
   PubMed Web of Science ®Google Scholar
• Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012;47:946–951.
   PubMed Web of Science ®Google Scholar
• Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007;130:1254–1262.
   PubMed Web of Science ®Google Scholar
• Von Glehn F, Farias AS, de Oliveira AC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18:1038–1041.
   PubMed Web of Science ®Google Scholar
• Harrer A, Tumani H, Niendorf S, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013;19:1209–1212.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Franciotta D, Rovaris M, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult Scler. 2014;20:1900–1903.
   PubMed Web of Science ®Google Scholar
• Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:298–304.
   PubMed Web of Science ®Google Scholar
• Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67:707–714.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011;76:1214–1221.
   PubMed Web of Science ®Google Scholar
• Martino G, Servalli C, Filippi M, et al. Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients. J Neuroimmunol. 1993;44:149–155.
   PubMed Web of Science ®Google Scholar
• Mavra M, Thompson EJ, Nikolic J, et al. The occurrence of oligoclonal IgG in tears from patients with MS and systemic immune disorders. Neurology. 1990;40:1259–1262.
   PubMed Web of Science ®Google Scholar
• Calais G, Forzy G, Crinquette C, et al. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler. 2010;16:87–92.
   PubMed Web of Science ®Google Scholar
• Lolli F, Franciotta D. Oligoclonal bands in tears. Mult Scler. 2010;16:760; author reply.
   PubMed Web of Science ®Google Scholar
• Ramsden DB. Multiple sclerosis: assay of free immunoglobulin light chains. Ann Clin Biochem. 2016 May 11;pii: 0004563216652175. [ Epub ahead of print].
   PubMedGoogle Scholar
• Goffette S, Schluep M, Henry H, et al. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:308–310.
   PubMed Web of Science ®Google Scholar
• Hassan-Smith G, Durant L, Tsentemeidou A, et al. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol. 2014;276:175–179.
   PubMed Web of Science ®Google Scholar
• Makshakov G, Nazarov V, Kochetova O, et al. Diagnostic and prognostic value of the cerebrospinal fluid concentration of immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis. PLoS One. 2015;10:e0143375.
   Google Scholar
• Presslauer S, Milosavljevic D, Huebl W, et al. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult Scler. 2016;22:502–510.
   PubMed Web of Science ®Google Scholar
• Solling K. Light chain polymerism in normal individuals in patients with severe proteinuria and in normals with inhibited tubular protein reabsorption by lysine. Scand J Clin Lab Invest. 1980;40:129–134.
   PubMed Web of Science ®Google Scholar
• Tate J, Bazeley S, Sykes S, et al. Quantitative serum free light chain assay–analytical issues. Clin Biochem Rev. 2009;30:131–140.
   PubMedGoogle Scholar
• Kaplan B, Golderman S, Yahalom G, et al. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J Immunol Methods. 2013;390:74–80.
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Tate JR, Merlini G. Is accuracy of serum free light chain measurement achievable? Clin Chem Lab Med. 2016;54:1021–1030.
   PubMed Web of Science ®Google Scholar
• Villar LM, Gonzalez-Porque P, Masjuan J, et al. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods. 2001;258:151–155.
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology. 2002;58:824–826.
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59:555–559.
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol. 2003;53:222–226.
   PubMed Web of Science ®Google Scholar
• Villar LM, Casanova B, Ouamara N, et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol. 2014;76:231–240.
   PubMed Web of Science ®Google Scholar
• Villar L, Sabada MC, Roldan E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest. 2005;115:187–194.
   PubMed Web of Science ®Google Scholar
• Villar L, Garcia-Barragan N, Espino M, et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler. 2008;14:183–187.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Gomez-Rial J, Hedstrom AK, et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler. 2008;14:1208–1213.
   PubMed Web of Science ®Google Scholar
• Garcia-Barragan N, Villar LM, Espino M, et al. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol. 2009;16:380–385.
   PubMed Web of Science ®Google Scholar
• Villar LM, Masterman T, Casanova B, et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol. 2009;211:101–104.
   PubMed Web of Science ®Google Scholar
• Bosca I, Villar LM, Coret F, et al. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult Scler. 2010;16:810–815.
   PubMed Web of Science ®Google Scholar
• Magraner MJ, Bosca I, Simo-Castello M, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012;54:5–12.
   PubMed Web of Science ®Google Scholar
• Villar LM, Garcia-Sanchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012;69:191–197.
   PubMedGoogle Scholar
• de la Concha EG, Cavanillas ML, Cenit MC, et al. DRB1*03:01 haplotypes: differential contribution to multiple sclerosis risk and specific association with the presence of intrathecal IgM bands. PLoS One. 2012;7:e31018.
   Google Scholar
• Villar LM, Picon C, Costa-Frossard L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015;22:1169–1175.
   PubMed Web of Science ®Google Scholar
• Villar LM, Costa-Frossard L, Masterman T, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol. 2015;77:447–457.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cermeno JC, Munoz-Negrete FJ, Costa-Frossard L, et al. Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. J Neurol Sci. 2016;360:41–44.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Sola P, Bedin R, et al. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255:1023–1031.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Simone AM, Bedin R, et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol. 2013;257:76–81.
   PubMed Web of Science ®Google Scholar
• Schneider R, Euler B, Rauer S. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol. 2007;14:907–911.
   PubMed Web of Science ®Google Scholar
• Beltran E, Obermeier B, Moser M, et al. Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain. 2014;137:2703–2714.
   PubMed Web of Science ®Google Scholar
• Stauch C, Reiber H, Rauchenzauner M, et al. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis. Mult Scler. 2011;17:327–334.
   PubMed Web of Science ®Google Scholar
• Espino M, Abraira V, Arroyo R, et al. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin Chim Acta. 2015;438:67–69.
   PubMed Web of Science ®Google Scholar
• Sandle LN. The management of external quality assurance. J Clin Pathol. 2005;58:141–144.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Koelman DL, Chahin S, Mar SS, et al. Acute disseminated encephalomyelitis in 228 patients: a retrospective, multicenter US study. Neurology. 2016;86:2085–2093.
   PubMed Web of Science ®Google Scholar
• Uher T, Horakova D, Tyblova M, et al. Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Mult Scler. 2016;22:770–781.
   PubMed Web of Science ®Google Scholar
• Hegen H, Auer M, Zeileis A, et al. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med. 2016;54:285–292.
   PubMed Web of Science ®Google Scholar
• Reiber H, Teut M, Pohl D, et al. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler. 2009;15:1466–1480.
   PubMed Web of Science ®Google Scholar
• Becker M, Latarche C, Roman E, et al. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol. 2015;15:79.
   PubMed Web of Science ®Google Scholar
• BioMS European network. Available from: www.biomseu.com
   Google Scholar
• Teunissen CE, Malekzadeh A, Leurs C, et al. Body fluid biomarkers for multiple sclerosis–the long road to clinical application. Nat Rev Neurol. 2015;11:585–596.
   PubMed Web of Science ®Google Scholar
• Stilund M, Gjelstrup MC, Petersen T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. Plos One. 2015;10:e0119681.
   PubMed Web of Science ®Google Scholar
• Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17:335–343.
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry. 2005;76:206–211.
   PubMed Web of Science ®Google Scholar
• Petzold A. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86:1388–1390.
   PubMed Web of Science ®Google Scholar
• Petzold A, Steenwijk MD, Eikelenboom JM, et al. Elevated CSF neurofilament proteins predict brain atrophy: a 15-year follow-up study. Mult Scler. 2016;22:1154–1162.
   PubMed Web of Science ®Google Scholar
• Bergman J, Dring A, Zetterberg H, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016;3:e271.
   PubMed Web of Science ®Google Scholar
• Arrambide G, Espejo C, Eixarch H, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016;87:1076–1084.
   PubMed Web of Science ®Google Scholar
• Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods. 2010;352:23–31.
   PubMed Web of Science ®Google Scholar
• Decker Y, Schomburg R, Nemeth E, et al. Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients. Mult Scler. 2016 Feb 16;pii: 1352458516631036. Epub ahead of print
   PubMedGoogle Scholar
• Huhn C, Selman MH, Ruhaak LR, et al. IgG glycosylation analysis. Proteomics. 2009;9:882–913.
   PubMed Web of Science ®Google Scholar
• Wuhrer M, Selman MH, McDonnell LA, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation. 2015;12:235.
   PubMed Web of Science ®Google Scholar
• Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133:1082–1093.
   PubMed Web of Science ®Google Scholar
• Canto E, Tintore M, Villar LM, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138:918–931.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Chen JQ, Papp G, Szodoray P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev. 2016 Sep 15;pii: S1568-9972(16)30195-1. Epub ahead of print.
   PubMedGoogle Scholar
• Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10:1252–1259.
   PubMed Web of Science ®Google Scholar
• Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013;73:729–740.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Haghikia A, Hellwig K, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012;79:2166–2170.
   PubMed Web of Science ®Google Scholar
• Ahlbrecht J, Martino F, Pul R, et al. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis. Mult Scler. 2016;22:1202–1214.
   PubMed Web of Science ®Google Scholar
• Bergman P, Piket E, Khademi M, et al. Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e219.
   Google Scholar
• Halbgebauer S, Huss A, Buttmann M, et al. Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. J Neurol. 2016;263:954–960.
   PubMed Web of Science ®Google Scholar